Cydan
700 Technology Square, 3rd Floor
Cambridge
Massachusetts
02139
United States
Tel: 617-231-6020
Website: http://www.cydanco.com/
Email: info@CydanCo.com
About Cydan
Cydan is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential. Cydan takes advantage of recent scientific breakthroughs in rare diseases and leveraging a creative approach to drug development and operates in an externally focused, highly collaborative and capital efficient manner.The accelerator is targeting programs that can make a significant impact on the lives of patients with rare diseases, focusing on advancements with large clinical benefit.
Cydan focuses on identifying promising assets with well-understood biology and proof-of-concept data in in vivo models from academia, industry and other sources. Data are generated during a rigorous diligence and de-risking process to enable subsequent financing and formation of successful stand-alone companies and strategic partnerships.
Based in Cambridge, Mass., Cydan was founded by a management team with extensive drug development, business development and commercialization experience across the biopharmaceutical, venture capital and consulting industries, and strong relationships with non-profit organizations and research foundations.
Cydan launched in 2013 with $26 million in financing led by New Enterprise Associates (NEA), Pfizer Venture Investments, Lundbeckfond Ventures and Bay City Capital with participation from Alexandria Real Estate Equities, Inc.
18 articles about Cydan
-
BioSpace Movers and Shakers: March 22
3/22/2019
Biotech and pharma companies make appointments to strengthen executive teams, with moves at Sanofi, Forma, Orchard, CLSA, Sangamo, and more. -
Cydan Expands Team to Accelerate Development of Innovative Treatments for Patients Living with Rare Diseases
3/20/2019
Yongchang Qiu, Ph.D., Named Vice President, Preclinical Development; Ryan Tyler, Ph.D., Named Senior Director, Preclinical Research; Niels Svenstrup, Ph.D., Promoted to Senior Vice President, Development
-
Cydan Announces Formation of Tiburio Therapeutics Inc. to Develop Treatments for Rare Neuroendocrine Tumors and Endocrine Diseases
1/3/2019
Tiburio raises $31M in a Series A round to advance two clinical stage compounds TBR-760, for the treatment of nonfunctioning pituitary adenoma (NFPA), and TBR-065 for rare endocrine diseases
-
Tiburio Launches With $31 Million and Two Compounds From Ipsen Targeting Rare Endocrine Diseases
1/3/2019
New biotech Tiburio has surged onto the scene with $31 million in financing and two novel Phase II-ready assets licensed from Ipsen Pharma. The new company, spun out of orphan drug accelerator Cydan is focused on rare endocrine diseases. -
Cydan Appoints Chief Business Officer
4/9/2018
Cydan announced that Imran A. Babar, PhD, has been named to the leadership team as chief business officer to help the company advance new and innovative therapies for patients living with rare monogenetic diseases.
-
Cydan snagged $34M to fund its rare disease pipeline and also tapped two new members of its executive leadership team.
-
Cydan Celebrates Rare Disease Day With Gift To Support The Children's National Rare Disease Institute
2/28/2017
-
Cydan Announces The Promotion Of James Mcarthur, Ph.D. To President, Research And Development
10/11/2016
-
Cydan Awards Five Scholarships To Support Innovations Impacting Individuals With Rare Conditions
7/13/2016
-
Cydan Churns Out Second Rare Disease Biotech Imara with $31 Million
4/14/2016
-
Cydan Announces The Promotion Of Dione Kobayashi, Ph.D., To Vice President, Preclinical Translation
11/4/2015
-
Cydan Announces Recipients Of Its MassChallenge Scholarship
6/24/2015
-
Cydan Supports Innovation For Patients With Rare Diseases Through MassChallenge Scholarships
3/19/2015
-
Orphan Drug Accelerator Cydan Supports Rare Disease Day® And Joins Patients, Advocates And Massachusetts Legislators To Raise Awareness For Rare Diseases
2/23/2015
-
Orphan Drug Accelerator Cydan Expands Transactional Expertise With Appointment Of Vered Bisker-Leib, Ph.D., MBA, As Chief Business Officer
10/15/2014
-
Cydan Expands Initial Financing to $26 Million; Additional Money Validates Unique Orphan Drug Accelerator Model
10/1/2013
-
Cydan, the NEA Startup Machine, Scours the Globe for Orphan Drugs
4/25/2013
-
Cydan Launches With $16 Million In Backing
4/11/2013